Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
|ClinicalTrials.gov Identifier: NCT00899808|
Recruitment Status : Withdrawn (not "applicable clinical trial")
First Posted : May 12, 2009
Last Update Posted : May 29, 2015
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.
|Condition or disease|
|Hematopoietic/Lymphoid Cancer Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific|
- Determine local-regional control in patients undergoing radiation therapy for cancer, as a function of expression of specific molecular/genetic markers.
- Determine complications of radiation therapy for patients undergoing radiation therapy for cancer.
OUTLINE: Previously collected tissue samples are analyzed using immunohistochemical staining and other molecular/genetic study methods to detect markers, including p53, cyclin D1, HER-2-neu, bcl-2/BAX, and EGFR. Patient charts are also reviewed with emphasis on local-regional relapse.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy|
|Study Start Date :||May 2006|
|Primary Completion Date :||May 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899808
|United States, New Jersey|
|Rutgers Cancer Institute of New Jersey - Robert Wood Johnson Medical School|
|New Brunswick, New Jersey, United States, 08903|
|Principal Investigator:||Bruce G. Haffty, MD||Rutgers Cancer Institute of New Jersey- Robert Wood Johnson Medical School|